logo
  

EC Approves Marketing Authorization Of DACOGEN For Acute Myeloid Leukemia

Astex Pharmaceuticals Inc. (ASTX) said that Janssen-Cilag International NV was notified that the European Commission has approved the marketing authorization for DACOGEN for the treatment of adult patients with newly diagnosed de novo or secondary acute myeloid leukemia or AML, according to the World Health Organization classification, who are not candidates for standard induction chemotherapy. Also, DACOGEN has been granted Orphan Drug designation to treat AML.

The data in support of the marketing authorization is based on the Phase 3 DACO-016 study that compared decitabine to patients' choice with physician advice of either supportive care or low-dose cytarabine in the treatment of older patients with AML.

DACO-016 was a Phase 3, randomized, open-label trial, in newly diagnosed patients =65 years of age with de novo or secondary AML and poor- or intermediate-risk cytogenetics.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Electric Company (GE) said it delivered a strong third quarter as orders grew, and margins continued to improve from a year ago. Adjusted GE Industrial organic profit increased 54% year-on-year, organically, driven primarily by increases at Aviation and Power, partially offset by decreases at... Ward Hill, Massachusetts-based Cedar's Mediterranean Foods is recalling Cedar's Organic Mediterranean Hommus citing undeclared pine nut, an allergen, the U.S. Food and Drug Administration said. The Cedar's Organic Mediterranean Hommus is packaged in a 10 oz. plastic container, with a UPC Code: 044115403028. Shares of UBS Group AG were gaining around 2 percent in Swiss trading after the banking major reported Tuesday higher profit in its third quarter with growth in net interest income. Further, the company said it intends to repurchase up to $0.6 billion of shares during the fourth quarter. The company will provide strategic update on February 1, 2022.
Follow RTT